Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jose Crossier

Clinical Nurse Specialist, Psychiatric/Mental Health Cape Coral, FL Nurse Practitioner

NPI 1396209649 CMS profile 11036084

514 Ne 16Th Pl Unit 4-5, Cape Coral, FL 33909

Open in the dashboard

General payments

$6,891

399 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Crossier of Cape Coral, FL is reported in the CMS Open Payments database as having received $6,891 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,897 87
2024 General $1,439 73
2023 General $1,742 123
2022 General $1,465 98
2021 General $348 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Crossier
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Jose Crossier were reported at $1,897. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Jose Crossier Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $348 $153 $44–$540 $132
2022 $1,465 $207 $60–$748 $149
2023 $1,742 $197 $55–$898 $160
2024 $1,439 $189 $49–$804 $164
2025 $1,897 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $936 56 payments
  2. ITI, Inc. $910 83 payments
  3. Teva Pharmaceuticals USA, Inc. $805 32 payments
  4. Otsuka America Pharmaceutical, Inc. $753 38 payments
  5. Ironshore Pharmaceuticals Inc. $430 42 payments
  6. Janssen Pharmaceuticals, Inc $410 16 payments
  7. Tempus AI, Inc $350 19 payments
  8. Alkermes, Inc. $341 14 payments
  9. Almatica Pharma LLC $326 20 payments
  10. Axsome Therapeutics, Inc. $231 11 payments
  11. Other $1,398 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,690 397 payments
  2. Education $201 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $768 47 payments
  2. REXULTI $616 32 payments
  3. CAPLYTA Psychiatry $541 66 payments
  4. Austedo XR $422 19 payments
  5. CAPLYTA Psychiatry $369 17 payments
  6. ABILIFY MAINTENA $349 15 payments
  7. LYBALVI $341 14 payments
  8. INVEGA SUSTENNA $340 13 payments
  9. LOREEV XR $326 20 payments
  10. ARISTADA $315 13 payments
  11. Other $4,336 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

2,469

Median for Nurse Practitioner: 389

Drug cost

$119,504

Median for Nurse Practitioner: $21,885

Branded share of claims

7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 35 $50,292
Caplyta Lumateperone Tosylate Brand 15 $25,326
Trintellix Vortioxetine Hydrobromide Brand 19 $9,646
Vilazodone Hcl Generic 59 $6,112
Lurasidone Hcl Generic 53 $4,151
Duloxetine Hcl Generic 32 $3,513
Quetiapine Fumarate Generic 242 $2,653
Eszopiclone Generic 40 $2,039
Memantine Hcl Generic 129 $1,667
Mirtazapine Generic 115 $1,649

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$38,895

Medicare's payments for the services billed

Medicare patients

44

Average age 72

Services billed

538

25 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 61%
Ischemic heart disease 50%
Chronic kidney disease 32%
COPD 32%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $243
$243 15 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $215
$215 — —
VRAYLAR
  • AbbVie, Inc. $204
$204 — —
LOREEV XR
  • Almatica Pharma LLC $133
$133 — —
Auvelity
  • Axsome Therapeutics, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record